fda warning letter glp-1 solution september 9 2025 FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

25.29

★★★★☆4.8 (126)

FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

21.53

★★★★★4.9 (98)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

27.96

★★★★★5.0 (157)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

29.20

★★★★★4.7 (84)

September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines

29.93

★★★★★4.9 (203)

FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers

28.78

★★★★★5.0 (176)

Alarming rise in weight loss drug overdoses

29.00

★★★★★4.8 (132)